Scholar Rock Holding (SRRK) Change in Account Payables (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Change in Account Payables of -$1.1 million for Q1 2026, up 80.82% year-over-year from -$600032.3 in Q1 2025, and down 130.66% quarter-over-quarter from $3.5 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Change in Account Payables (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Change in Account Payables history runs 10 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 80.82% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at $4.8 million (up 202.21% YoY), while the FY2025 annual figure was $208000.0, down 96.86% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$1.1 million, down from $3.5 million in the prior quarter.
- The five-year high for Change in Account Payables was $6.0 million in Q4 2024, with the low at -$5.7 million in Q1 2025.
- The 5-year median for Change in Account Payables is -$274000.0 (2023), against an average of $292529.4.
- Peak annual rise in Change in Account Payables reached 648.68% in 2025, while the deepest fall reached 827.54% in 2025.
- Scholar Rock Holding's Change in Account Payables stood at $2.0 million in 2022, then slipped by 24.92% to $1.5 million in 2023, then jumped by 302.4% to $6.0 million in 2024, then tumbled by 41.25% to $3.5 million in 2025, then slumped by 130.66% to -$1.1 million in 2026.
- Business Quant data shows SRRK's Change in Account Payables at -$1.1 million in Q1 2026, $3.5 million in Q4 2025, and $5.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Scholar Rock Holding | 7.25 Bn | 7.25 Bn | - | 1.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.75 Mn |
| Mar 31, 2026 | -1.09 Mn |
| Dec 31, 2025 | 3.54 Mn |
| Sep 30, 2025 | 5.66 Mn |
| Jun 30, 2025 | -3.33 Mn |
| Mar 31, 2025 | -5.66 Mn |
| Dec 31, 2024 | 6.02 Mn |
| Sep 30, 2024 | 756,000.00 |
| Jun 30, 2024 | 460,000.00 |
| Mar 31, 2024 | -610,000.00 |
| Dec 31, 2023 | 1.50 Mn |
| Sep 30, 2023 | -1.08 Mn |
| Jun 30, 2023 | -676,000.00 |
| Mar 31, 2023 | -274,000.00 |
| Dec 31, 2022 | 1.99 Mn |
| Sep 30, 2022 | -851,000.00 |
| Jun 30, 2022 | 186,000.00 |
| Mar 31, 2022 | -1.58 Mn |
| Dec 31, 2021 | 2.21 Mn |
| Sep 30, 2021 | 585,000.00 |